Doug Kohrs to join Proto Labs Board of Directors
03 Abril 2012 - 2:19PM
Business Wire
Proto Labs, Inc. (NYSE: PRLB), a leading online and
technology-enabled quick-turn manufacturer, today announced that
Doug Kohrs, President and CEO of Tornier, N.V., a global medical
device company, was appointed to its Board of Directors, bringing
the board’s size to 9 members.
“Doug has impressive leadership experience with a variety of
highly successful, technology-based public companies, said Brad
Cleveland, President and CEO of Proto Labs. “We are excited to
welcome Doug to our Board and look forward to benefitting from his
insights.”
Prior to joining Tornier, Mr. Kohrs served as President and
Chief Executive Officer of American Medical Systems Holdings, Inc.,
a publicly held medical device company that was acquired by Endo
Pharmaceuticals Holdings, Inc. Mr. Kohrs also served as Chairman of
the Board of American Medical Systems Holdings.
During the past 10 years, Mr. Kohrs has served on the board of
directors of nine different medical device companies, including ev3
Inc., a publicly held medical device company that was acquired by a
wholly-owned subsidiary of Covidien Group S.a.r.l, and Kyphon,
Inc., a publicly held medical device company that was acquired by
Medtronic, Inc.
Mr. Kohrs holds a Master of Business Administration from
Northeastern University, a Bachelor of Science in Bioengineering
from Texas A&M University and a Bachelor of Arts in Engineering
Sciences from Austin College.
About Proto Labs, Inc.Proto Labs is a leading online and
technology-enabled quick-turn manufacturer of custom parts for
prototyping and short-run production. Proto Labs provides “Real
Parts, Really Fast” to product developers worldwide. Proto Labs
utilizes computer numerical control (CNC) machining and injection
molding to manufacture custom parts for our customers. For more
information, visit protolabs.com.
Cautionary Note Regarding Forward-Looking
StatementsStatements contained in this press release regarding
matters that are not historical facts are “forward-looking
statements” within the meaning of The Private Securities Litigation
Reform Act of 1995. These statements involve known and unknown
risks, uncertainties and other factors which may cause the results
of Proto Labs to be materially different than those expressed or
implied in such statements. Certain of these risk factors and
others are described in the “Risk Factors” section of the
final prospectus relating to the initial public offering, as filed
with the SEC, as well as in Proto Labs’ subsequent reports filed
with the SEC. Other unknown or unpredictable factors also could
have material adverse effects on Proto Labs’ future results. The
forward-looking statements included in this press release are made
only as of the date hereof. Proto Labs cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, Proto Labs expressly disclaims
any intent or obligation to update any forward-looking statements
to reflect subsequent events or circumstances.
Proto Labs (NYSE:PRLB)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Proto Labs (NYSE:PRLB)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024